Introduction
The pathway for de novo biosynthesis of purine nucleotides is essential to sustain rapid and continuous growth of cancer cells:
P-Rib-PP-»PRA-»GAR-»-FGAR-»FGAM->AIR-• CAIR->SAICAR->AICAR-»FAICAR->IMP (1)
The antifolates methotrexate (MTX) and piritrexim (PTX) are potent inhibitors of the enzyme dihydrofolate reductase and they induce consequent accumulation of dihydrofolate in cells. Allegra et al. (1) found that human MCF-7 breast cancer cells exposed to 10 μΜ MTX accumulated dihydrofolate and the level of AICAR increased 3-fold. They concluded that the primary blockade of the purine pathway was at reaction 9 (AICAR->FAICAR) due to inhibition of AICAR transformylase by accumulated dihydrofolate.
We (3)]. These data strongly suggest that in leukaemia cells exposed to MTX, reactions / or 2 (P-Rib-PP->PRA->GAR) becomes rate-limiting for the flux through the de novo purine pathway. Preliminary evidence is presented in this communication that amido phosphoribosyltransferase, catalysing reaction 1, is the site of this inhibition. Mouse L1210 leukaemia cells were grown in RPMI 1640 medium (Flow Laboratories, Sydney, Australia) as described previously (2, 3) . Details of procedures for addition of drugs to cultures, sampling, extraction and quantification by HPLC and one-dimensional thin layer chromatography have been published (2, 3, 4) . P-Rib-PP was extracted from cells and assayed by conversion to UMP (5). Amido phosphoribosyltransferase was extracted from L1210 cells by sonication in 0.25 M sucrose, 1.0 mM MgCl 2 , 20 mM K. Hepes (pH 7.0), concentrated 10-fold, and assayed in mixtures (50 μΐ) containing: 50 mM K. Hepes (pH 7.2), 1.0 mM dithiothreitol, 1.0 mM MgCl 2 , 500 μΜ Mg 2 P-
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GMP
14 C]glutamine (10 Ci/mol, Du Pont, DE, USA), cell-free extract (37 μg protein) and Table 1 . Inhibitors of Amido Phosphoribosyltransferase from Mouse L1210 Leukaemia Cells Amido phosphoribosyltransferase was extracted and the rate of the reaction L-Gln + P-Rib-PP-«L-Glu + PP¡ + 5-phosphoribosylamine was determined as described under Materials and Methods. Reaction rates were calculated after subtraction of non-specific glutaminase activity (assay without 500 μΜ P-Rib-PP, 44.7 pmol glutamate/min/mg protein) and are expressed as percentage inhibition of the control activity (280 pmol glutamate/min/mg protein). a 500 μΜ concentration of a potential inhibitor. The P-Rib-PP-dependent rate of [ 14 C]glutamate formation was determined after chromatography of samples (7 μΐ) on poly(ethyleneimine)-cellulose plates with 0.28% (v/v) formic acid.
Effector
Results and Discussion
Analysis by HPLC of extracts prepared from LI 210 cells exposed to MTX (0.1 μΜ) for 2 h showed accumulations of AICAR (from a cellular concentration of 135 μΜ to 406 μΜ) and SAI CAR (from 44 μΜ to 173 μΜ) and decreases in ATP (1130 μΜ to 534 μΜ) and GTP (233 μΜ to 69 μΜ). These data are consistent with a metabolic cross-over point at reaction 9 indicating that MTX induces inhibition of AICAR transformylase as proposed by Allegra et al. (1) . However, analysis by one-dimensional chromatography of extracts prepared from cells treated with MTX (0.1 μΜ) for 2 h where [ 14 C]glycine (125 μΜ, 22.4 Ci/mol) was added with the MTX, showed accumulation of GAR (564 μΜ to 714 μΜ) and decreases in FGAR (158 μΜ to 143 μΜ) and AIR (203 μΜ to 98 μΜ) consistent with inhibition of reaction 3 catalysed by GAR transformylase. In addition, the cellular concentration of P-Rib-PP increased (64 μΜ to 135 μΜ).
These data indicate that MTX induces inhibition of the two transformylase reactions of the de novo purine pathway in growing leukaemia cells. The accumulations of AICAR and SAICAR could arise from intermediates pre-existing in the pathway after reaction 3 (i. e. FGAR->FGAM->AIR->CAIR->SAICAR-> AICAR). The more proximal inhibition at reaction 3 could be the primary site of inhibition, consistent with MTX abolishing the azaserine-induced accumulation of FGAR polyphosphates (3). However, the accumulation of GAR observed is moderate and inconsistent with the complete blockade of the pathway. The 2.1-fold accumulation of P-Rib-PP observed suggests that reaction 1 catalysed by amido phosphoribosyltransferase may also be inhibited in cells treated with MTX and, as a more proximal reaction, could be the primary site of inhibition.
A variety of purine nucleotides and folate derivatives were therefore tested as inhibitors of amido phosphoribosyltransferase in vitro. Table 1 shows that GMP, IMP and AMP are effective feed-back inhibitors of this enzyme which has been widely reported. AICAR, a purine intermediate which accumulates 2 h after MTX addition, is also inhibitory. Folate and dihydrofolate are potent inhibitors of amido phosphoribosyltransferase but tetrahydrofolate and N 5 -formyl tetrahydrofolate are not. MTX does not inhibit the enzyme but MTX-Glu 5 is an effective inhibitor, while PTX is the most potent of the inhibitors.
Conclusions
Measurements of total concentrations of purine intermediates and pulse-labelling with [
14 C]glycine of L1210 cells growing in culture suggest that MTX induces primary inhibition of the de novo purine pathway at amido phosphoribosyltransferase. In support of this proposal, we have found that AICAR, dihydrofolate and MTX-Glu 5 , which accumulate in cells exposed to MTX, are effective inhibitors of this enzyme in vitro.
